678.91 USD
-10.54
1.53%
At close Aug 25, 4:00 PM EDT
After hours
678.95
+0.04
0.01%
1 day
-1.53%
5 days
1.36%
1 month
-4.62%
3 months
-5.76%
6 months
8.27%
Year to date
19.90%
1 year
24.01%
5 years
346.65%
10 years
260.28%
 

About: McKesson Corp is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Employees: 51,000

0
Funds holding %
of 7,429 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

65% more first-time investments, than exits

New positions opened: 172 | Existing positions closed: 104

41% more call options, than puts

Call options by funds: $632M | Put options by funds: $447M

10% more capital invested

Capital invested by funds: $72.6B [Q1] → $80.1B (+$7.49B) [Q2]

1.62% more ownership

Funds ownership: 86.09% [Q1] → 87.71% (+1.62%) [Q2]

1% more funds holding

Funds holding: 1,724 [Q1] → 1,749 (+25) [Q2]

5% less repeat investments, than reductions

Existing positions increased: 614 | Existing positions reduced: 649

33% less funds holding in top 10

Funds holding in top 10: 52 [Q1] → 35 (-17) [Q2]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$772
14%
upside
Avg. target
$794
17%
upside
High target
$810
19%
upside

3 analyst ratings

positive
67%
neutral
33%
negative
0%
Wells Fargo
Stephen Baxter
14%upside
$772
Equal-Weight
Maintained
13 Aug 2025
Morgan Stanley
Erin Wright
19%upside
$810
Overweight
Maintained
16 Jul 2025
Evercore ISI Group
Elizabeth Anderson
18%upside
$800
Outperform
Maintained
9 Jul 2025

Financial journalist opinion

Based on 20 articles about MCK published over the past 30 days

Positive
Zacks Investment Research
1 week ago
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
Negative
Zacks Investment Research
2 weeks ago
4 Dental Supplies Stocks Likely to Gain Amid Rising Tariff Risks
Here, we discuss four stocks from the Dental Supplies industry that are likely to generate wealth for investors amid tariff uncertainty. These are MCK, CAH, WST and COO.
4 Dental Supplies Stocks Likely to Gain Amid Rising Tariff Risks
Positive
Zacks Investment Research
2 weeks ago
Here's Why McKesson (MCK) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why McKesson (MCK) is a Strong Value Stock
Positive
Zacks Investment Research
2 weeks ago
Dividend Watch: 3 Companies Boosting Payouts
Everybody loves dividends, as they provide a passive income stream, limit drawdowns in other positions, and provide more than one way to profit from an investment.
Dividend Watch: 3 Companies Boosting Payouts
Neutral
Zacks Investment Research
2 weeks ago
MCK Stock Down Despite Q1 Earnings Beat & Raised '26 EPS View
McKesson beats on Q1 earnings and raises FY26 EPS view, but shares slip as gross margin narrows and spin-off plans weigh on investors' sentiment.
MCK Stock Down Despite Q1 Earnings Beat & Raised '26 EPS View
Neutral
Zacks Investment Research
2 weeks ago
Compared to Estimates, McKesson (MCK) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for McKesson (MCK) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Compared to Estimates, McKesson (MCK) Q1 Earnings: A Look at Key Metrics
Neutral
Seeking Alpha
2 weeks ago
McKesson Corporation (MCK) Q1 2026 Earnings Call Transcript
McKesson Corporation (NYSE:MCK ) Q1 2026 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Brian S. Tyler - CEO & Director Britt J.
McKesson Corporation (MCK) Q1 2026 Earnings Call Transcript
Positive
Zacks Investment Research
2 weeks ago
McKesson (MCK) Surpasses Q1 Earnings and Revenue Estimates
McKesson (MCK) came out with quarterly earnings of $8.26 per share, beating the Zacks Consensus Estimate of $8.23 per share. This compares to earnings of $7.88 per share a year ago.
McKesson (MCK) Surpasses Q1 Earnings and Revenue Estimates
Positive
Reuters
2 weeks ago
Mckesson lifts annual profit forecast on robust demand for specialty drugs
U.S. drug distributor McKesson raised its annual profit forecast and beat Wall Street earnings estimates on Wednesday, banking on robust demand for specialty medicines.
Mckesson lifts annual profit forecast on robust demand for specialty drugs
Neutral
Business Wire
2 weeks ago
McKesson Corporation Reports Fiscal 2026 First Quarter Results and Raises Full Year Adjusted EPS Guidance
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2026 first quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, August 6 at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and ar.
McKesson Corporation Reports Fiscal 2026 First Quarter Results and Raises Full Year Adjusted EPS Guidance
Charts implemented using Lightweight Charts™